CN103768283A - 一种治疗多种眼疾的中药 - Google Patents
一种治疗多种眼疾的中药 Download PDFInfo
- Publication number
- CN103768283A CN103768283A CN201410048980.2A CN201410048980A CN103768283A CN 103768283 A CN103768283 A CN 103768283A CN 201410048980 A CN201410048980 A CN 201410048980A CN 103768283 A CN103768283 A CN 103768283A
- Authority
- CN
- China
- Prior art keywords
- flos
- herba
- semen
- chinese medicine
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 210000003608 fece Anatomy 0.000 claims abstract description 10
- 241000628997 Flos Species 0.000 claims description 55
- 210000000582 semen Anatomy 0.000 claims description 37
- 238000011282 treatment Methods 0.000 claims description 20
- 241000241413 Propolis Species 0.000 claims description 10
- 229940069949 propolis Drugs 0.000 claims description 10
- 244000293323 Cosmos caudatus Species 0.000 claims description 9
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 9
- 241000003857 Parmelia saxatilis Species 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 47
- 230000004438 eyesight Effects 0.000 abstract description 36
- 239000008280 blood Substances 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 17
- 208000003464 asthenopia Diseases 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 208000002177 Cataract Diseases 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 210000001328 optic nerve Anatomy 0.000 abstract description 2
- 230000005855 radiation Effects 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241001113925 Buddleja Species 0.000 abstract 1
- 240000008365 Celosia argentea Species 0.000 abstract 1
- 235000000722 Celosia argentea Nutrition 0.000 abstract 1
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 244000124209 Crocus sativus Species 0.000 abstract 1
- 235000015655 Crocus sativus Nutrition 0.000 abstract 1
- 241000195955 Equisetum hyemale Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000010254 Jasminum officinale Nutrition 0.000 abstract 1
- 240000005385 Jasminum sambac Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 241000003856 Parmelia Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 241000612118 Samolus valerandi Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 241001146210 Senecio scandens Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 241001312894 Trollius chinensis Species 0.000 abstract 1
- 240000001260 Tropaeolum majus Species 0.000 abstract 1
- 235000004424 Tropaeolum majus Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000013871 bee wax Nutrition 0.000 abstract 1
- 229940105847 calamine Drugs 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 229910052864 hemimorphite Inorganic materials 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 244000112814 pipewort Species 0.000 abstract 1
- 235000013974 saffron Nutrition 0.000 abstract 1
- 239000004248 saffron Substances 0.000 abstract 1
- 235000008113 selfheal Nutrition 0.000 abstract 1
- 235000014692 zinc oxide Nutrition 0.000 abstract 1
- 239000011787 zinc oxide Substances 0.000 abstract 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 34
- 210000004185 liver Anatomy 0.000 description 33
- 201000010099 disease Diseases 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 208000002193 Pain Diseases 0.000 description 23
- 235000009508 confectionery Nutrition 0.000 description 17
- 230000008961 swelling Effects 0.000 description 17
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 12
- 208000001491 myopia Diseases 0.000 description 12
- 206010034960 Photophobia Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000004379 myopia Effects 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 206010010741 Conjunctivitis Diseases 0.000 description 9
- 239000003440 toxic substance Substances 0.000 description 9
- 206010010726 Conjunctival oedema Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241000475481 Nebula Species 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 241000909851 Epiphora Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 201000004484 acute conjunctivitis Diseases 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 210000000744 eyelid Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000016747 lacrimal apparatus disease Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010015958 Eye pain Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010047531 Visual acuity reduced Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 208000001749 optic atrophy Diseases 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 201000010041 presbyopia Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004223 radioprotective effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000013433 lightheadedness Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000003578 releasing effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009978 visual deterioration Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 208000034700 Vitreous opacities Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000005547 chronic conjunctivitis Diseases 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- -1 contains several: 1 Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004436 pseudomyopia Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Abstract
本发明公开了一种治疗多种眼疾的中药。由下列27味中药材制成:藏红花,枸杞子,沙苑子,女贞子,车前子,五味子,青葙子,决明子,金银花,茉莉花,白菊花,石花,密蒙花,金莲花,旱莲花,谷精草,夏枯草,木贼草,夜明砂,珍珠,炉甘石,薄荷,蒲公英,千里光,黄柏,蜂胶,甘草。本发明具有活血化瘀、清障明目,疏风散热,凉血解毒,营养视神经,修复眼细胞,改善微循环,缓解眼疲劳,抗氧化,抗辐射等功效。本发明配方合理,疗效迅速,无异味,无刺激,无副毒作用,生产工艺简单,使用安全方便,疗效显著。
Description
技术领域
本发明属于中药技术领域,具体地说是以中药为原料制成的治疗多种眼疾的外用中药制剂及其制备方法。
背景技术
眼疾是临床中最常见的疾病,发病人群涉及各个年龄段。在众多眼科疾病中,其中青少年近视最多。据卫生部统计:我国目前青少年近视发病率高达50%-60%,近视群体约为2亿人,严重影响了青少年的健康生活,这一结果已对实现中国二十一世纪的健康目标构成了严重挑战。数据显示:我国近视人数全球第一,现有近视患者已超过三亿人,占世界近视人数的33%,远远高于世界平均22%的比例;我国近视率排名世界第二,每年新增近视眼约为10%,仅次于“近视第一大国”日本。近视眼已被列为世界三大疾病之一。
在老年群体中,常见的有老视眼、白内障、青光眼,老年黄斑变性、角膜炎、结膜炎、视网模病变、屈光不正,眼底疾病等,严重的可导致失明。据世界卫生组织统计,全球盲人数量约4000万-4500万,全球每年新增盲人数量为100万-200万。我国是世界上盲人最多的国家之一,每一分钟就增加一个盲人,目前患病人数约为700万,主要原因是因白内障造成的。
目前,在我国治疗眼疾多采用吃药和外用眼药的方法,严重的做手术。眼药分为软膏剂和滴眼剂两大类,但不论是软膏剂还是滴眼剂都含有防腐剂,市售滴眼剂主要有一下几种:1,抗生素类,主要用于治疗眼部感染,如氨基糖苷类,毒性较大,如庆大霉素、新霉素、妥布霉素等;喹渃酮类,毒性相对稍小,如氧氟沙星、环丙沙星及左氧氟沙星等;2,抗病毒类,以阿昔洛韦使用较多,副作用的发生机率较大,其它抗病毒药如更昔洛韦、病毒唑等亦有副作用;3,抗真菌滴眼剂,以两性霉素副作用较大,其次为酮康唑及氟康唑;以上这些眼药长期滥用容易导致眼睛菌群失调,表现为异物感、干涩、发痒,重者有疼痛、畏光、流泪及视力下降,分泌物较少,双侧眼睑及结膜红肿等。另外还有激素类,此类眼药具有抗炎、抗过敏等作用,可缓解或治疗干眼、过敏等眼部问题,但长期使用(三个月以上)会引起眼压增高,甚至引起神经损害和视力下降,视神经萎缩,导致激素型青光眼,更严重者会导致失明。
总之,目前市面上没有毒副作用的滴眼剂很少,基本上都含有防腐剂,药物的治疗作用和毒副作用在治疗过程中很难做到两全,因此急需一种即无毒副作用,无任何添加剂,治疗效果又好的外用纯中药制剂。
发明内容
本发明就是针对以上现有技术领域存在的弊端,提供一种具有活血化瘀,清障明目,疏风散热,消肿散结,凉血解毒,营养视神经,修复眼细胞,缓解眼疲劳,提高视力,抗氧化,抗辐射的外用中药液体制剂。本发明以中医透皮疗法理论为基础,来治疗、预防和调理多种眼疾。不但疗效迅速,而且不用吃药、不打针,不用滴入眼睛内,具有安全、速效、方便、无异味、无刺激、无副毒作用等优点。
本发明是发明人总结十余年来丰富临床经验,继承世家传统医术,发掘祖国医学精髓,经临床数千人满意的疗效反馈,不断加以总结探索而研发出来的。
本发明由下列中药按重量配比制成:
藏红花3-5g、枸杞子9-15g、沙苑子5-15g、女贞子5-15g、车前子5-15g、五味子3-9g、青葙子5-15g、决明子1-5g、金银花9-15g、茉莉花1-5g、白菊花10-20g、石花3-9g、密蒙花1-5g、金莲花1-5g、旱莲花1-5g、谷精草6-12g、夏枯草5-15g、木贼草5-15g、夜明砂6-12g、珍珠0.5-2.5g、炉甘石3-9g、薄荷3-9g、蒲公英5-15g、千里光6-12g、黄柏3-9g、蜂胶10-20g、甘草1-5g。
最优重量配比为:
藏红花4g、枸杞子12g、沙苑子10g、女贞子10g、车前子10g、五味子6g、青葙子10g、决明子3g、金银花12g、茉莉花3g、白菊花15g、石花6g、密蒙花3g、金莲花3g、旱莲花3g、谷精草9g、夏枯草10g、木贼草10g、夜明砂9g、珍珠1.5g、炉甘石6g、薄荷6g、蒲公英10g、千里光9g、黄柏6g、蜂胶15g、甘草3g。
将上述各组分制备成本发明一种治疗多种眼疾的中药的方法是按下述步骤完成的:
(A)称取各重量份:藏红花3-5g、枸杞子9-15g、沙苑子5-15g、女贞子5-15g、车前子5-15g、五味子3-9g、青葙子5-15g、决明子1-5g、金银花9-15g、茉莉花1-5g、白菊花10-20g、石花3-9g、密蒙花1-5g、金莲花1-5g、旱莲花1-5g、谷精草6-12g、夏枯草5-15g、木贼草5-15g、夜明砂6-12g、珍珠0.5-2.5g、炉甘石3-9g、薄荷3-9g、蒲公英5-15g、千里光6-12g、黄柏3-9g、蜂胶10-20g、甘草1-5g;
(B)以上按照现有公知技术常规方法制成液体完成本发明。
在此对以上各中药组分加以说明,其中藏红花:味甘、性平,归心、肝经;具有活血化瘀,开郁散结,抗菌消炎,抗疲劳,抗肿瘤,增强机体免疫,平衡阴阳的作用;主治瘀肿疼痛,跌打损伤等症。枸杞子:味甘、性平,归肝、肾经;具有明目安神,祛风治虚,延年益寿,坚筋骨的作用;能补肝肾,益精气,长肌肉,改善气色。沙苑子:味甘、性温,归肝、肾经;具有益血养肾,补肝明目的作用;《本草汇言》:沙苑疾黎,补肾涩精之药也。能养肝明目,润泽瞳人等;现代医学研究表明:沙菀子含有多种氨基酸、多肽、蛋白质、鞣质等,具有很好的抗疲劳作用;主治肝肾不足引起的头昏目花,目暗不明等症。女贞子:味甘、苦,性凉,归肝、肾经;具有补益肝肾,清热明目的作用;主治肝肾阴虚,头昏目眩,目暗不明,视物不清等症。车前子:味甘、性寒;归肺、胃、肾经;具有利尿通淋,清肝明目的作用;主治小便短赤,热淋、血淋、石淋,目赤肿痛,目暗昏花等症。五味子:味酸、甘,性温,归心、脾、肾经;具有敛肝滋阴,生津敛汗,补虚明目,强阴涩精的作用;现代医学研究表明:五味子能保护五脏,抗氧化,抗衰老,特别是具有保肝及再生肝脏组织的作用,能增强体能和增进视力。青葙子:味苦,性微寒,归肝经;具有清肝泻火,明目退翳的作用;主治目赤红肿,视物昏花,目生翳障等证。决明子:味甘、苦、咸,性微寒;归肝、大肠经;清热明目,润肠通便。主治目赤涩痛,羞明多泪,头痛目眩,目暗不明,青盲内障等症。金银花:味甘、性寒,归肺、心、肾经;具有清热解毒,疏散风热,凉血解毒的作用;金银花气味芳香,既能清透疏表,又能解血分热毒,对眼疲苈有一定的治疗作用。茉莉花:味辛、微甘,性温;具有清肝明目,杀菌消炎,舒缓神经,安定情绪,去除口臭体臭,理气止痛,辟移开郁的作用;主治目赤肿痛,迎风流泪,疮疡,皮肤溃烂,结膜炎等病症。白菊花:味辛、苦,性寒;归肝、肺经;具有疏风散热,平肝明目,清热解毒的作用;主治肝阳上亢,头痛目眩,畏光多泪,目赤肿痛,肝肾阳虚所致的眼目昏花,热毒疮肿等证。石花:味甘、苦,性寒,归肝经;密蒙花:味甘、性微寒,归肝经;具有清热养肝,明目退翳的作用;主治肝火上炎,目生翳障,羞明多泪,目赤肿痛,目暗干涩等症。旱莲花:味甘、性凉,具有清热明目,解毒消肿的作用,主治目赤肿痛,恶毒大疮的症。金莲花:味苦,性寒;清热明目,解毒消炎;主治上感,急性结膜炎,翳障等症。谷精草:味辛、甘,性凉,归肝、胃经;具有疏风散热,明目退翳的作用;用于风热目疾,肿痛羞明,翳模遮睛等症。夏枯草:味辛、苦,性寒,入肝、胆经;清肝火,散瘀结,用于肝火上炎,目赤肿痛,目珠疼痛,头昏目眩等症。木贼草:味甘、苦,性平,归肺、肝、胆经;疏风热,退翳膜;用于风热引起的目赤翳障等症。夜明砂:味辛、性寒,入肝经;清热明目,散瘀消积。主治青盲,雀盲,内外翳障,痈肿等症。珍珠:味甘、咸,性寒;入心、肝经;镇心定惊,清肝明目,收敛生肌;主治目赤红肿,翳障胬肉等症。炉甘石:味甘、性平,入肝、脾、肺经;消肿毒,明目祛翳,退赤膜,收湿除烂,敛疮生肌;主治下疳阴疮、目暴赤肿,翳障,睑弦赤烂,溃疡不敛,皮肤湿疮等症。薄荷:味辛,性凉,入肝、肺经;疏风散热,清香升散,清利头目,利咽喉,透疹毒,疏肝解郁,辟秽解毒;主治外感风邪头痛,目赤,口疮,牙痛,皮肤骚痒等症。蒲公英:味甘,性寒,入肝、胃经;清热解毒,消痈散结,清肝明目,利尿通淋;主治急性结膜炎,目赤肿痛等症。《文献摘要》“蒲公英4两,治眼疾肿痛,或胬肉遮睛,或赤脉络目,或目睛胀痛,或目痛连脑,或羞明多泪,一切虚火实热。千里光:味苦、性寒;清热解毒,明目祛翳,凉血,消炎止痛,杀虫止痒,去腐生机;主治风火赤眼,目生翳障等证。黄柏:味苦、性寒;入肾、膀胱、大肠经;清热燥湿,泻火败毒,退虚热;主治温热泻痢,口舌生疮,目赤肿痛等症。蜂胶:味辛、性温。入肝、脾经;具有杀菌,抗感染,消炎,抗病毒,抗辐射,抗溃疡,抗缺氧,抗疲劳的作用;蜂胶富含各种维生素,能清除氧自由基,调节内分泌,促进细胞再生,恢复器官组织的病变损伤,能祛眼部细纹,并可中和体内的有害物质。生甘草:味甘、性平,归肺、脾、胃经;能补脾益气,清热解毒,祛痰止渴,缓急止痛,调和诸药,解百毒;在本方中起到调和作用。
以上诸药合用,具有活血化瘀,清热败毒,抗菌消炎,养血明目,消肿散结,抗氧化,抗辐射,营养视神经,修复眼细胞,缓解视疲劳,提高视力,改善微循环等功效。
本发明药物具有以下优点:
1.本发明为纯中药制剂,配方合理,药效迅速、确切、持久。
2.本发明价格低廉,使用方便、舒适安全,治愈率高。
3.本发明不伤皮肤,无异味、无刺激、无副毒作用。
4.本发明集预防,调理,治疗为一体。
具体实施方式
实施例1
按照下述重量份,称取各组分:
藏红花3g、枸杞子9g、沙苑子5g、女贞子5g、车前子5g、五味子3g、青葙子5g、决明子g、金银花9g、茉莉花1g、白菊花10g、石花3g、密蒙花1g、金莲花1g、旱莲花1g、谷精草6g、夏枯草5g、木贼草5g、夜明砂6g、珍珠0.5g、炉甘石3g、薄荷3g、蒲公英5g、千里光6g、黄柏3g、蜂胶10g、甘草1g。
[制作方法]
将上述各组分按常规公知技术方法制成液体完成本发明。
[使用功效]
活血化瘀,清热败毒,抗菌消炎,养血明目,消肿散结。抗氧化,抗辐射,营养修复视神经及细胞,缓解眼疲劳,提高视力。
[用法用量]
取本品0.3-0.5mL(闭眼>涂抹在上下眼皮或上下眼眶,每日3-5次,使用时配合按摩上下眼眶疗效更佳;末成年人应在成年人指导下少量使用,使用时将本发明用两倍以上纯净水或凉开水进行稀释后再使用(每日2-3次,每次0.1-0.2mL)。
[适应范围]
适用于火眼赤肿,目生翳障,迎风流泪,畏光羞明,外伤瘀肿,目暗昏花等症者,如视神经萎缩,急慢性结膜炎,角膜炎,麦粒肿,早期白内障,玻璃体混浊,青少年近视眼,老视眼,视疲劳等。尤其对假性近视眼,老视眼及“火眼”有特效;对经常读书看报、看电视、上电脑的人群有保护视力和预防眼疾的功效,并可祛除眼角细纹。
[注意事项]
孕妇、哺乳期及眼底出血倾向者禁用;7岁以下儿童禁用;眼皮溃烂者禁用;皮肤过敏者慎用;儿童必须在成人的监护下使用,请将此药品放在儿童不能接触的地方。
[禁忌]当药品性状发生改变时,禁用。
[贮藏]密闭,放在儿童不能触及的地方常温下避光保存。
[有效期]常温下36个月。
实施例2
按照下述重量份,称取各原料:
藏红花5g、枸杞子15g、沙苑子15g、女贞子15g、车前子15g、五味子9g、青葙子15g、决明子5g、金银花15g、茉莉花5g、白菊花20g、石花9g、密蒙花5g、金莲花5g、旱莲花5g、谷精草12g、夏枯草15g、木贼草15g、夜明砂12g、珍珠2.5g、炉甘石9g、薄荷9g、蒲公英15g、千里光12g、黄柏9g、蜂胶20g、甘草5g。
[制作方法][使用功效][使用方法][适应范围][注意事项][禁忌][贮藏][有效期]同实施例1。
实施例3
按照下述重量称取各原料:
藏红花4g、枸杞子12g、沙苑子10g、女贞子10g、车前子10g、五味子6g、青葙子10g、决明子3g、金银花12g、茉莉花3g、白菊花15g、石花6g、密蒙花3g、金莲花3g、旱莲花3g、谷精草9g、夏枯草10g、木贼草10g、夜明砂9g、珍珠1.5g、炉甘石6g、薄荷6g、蒲公英10g、千里光9g、黄柏6g、蜂胶15g、甘草3g。
[制作方法][使用功效][使用方法][适应范围][注意事项][禁忌][贮藏][有效期]同实施例1。
临床疗效观察
1、临床资料
选择门诊病例共380例,其中试验组260例,占68.4%,对照组120例,占31.6%。全部病例均符合病例选择标准。320例病例采用完全随机分组,患者严格控制可变因素和自行联合用药,以保证实验的可比性,观察期间两组均停用其它药物。
2、观察方法:
2.1、试验组:外用本发明:一种治疗多种眼疾的中药,一次0.3-0.5mL,3次/日,1周为一疗程;
2.2、对照组:使用色甘酸钠滴眼液,按说明书使用,1周为一疗程。
2.3、试验组合对照组均在一周后观察用药效果。
3、观察结果
3.1、试验组主要症状治疗1个月后前后改善情况,详见表1。
表1试验组主要症状治疗前后改善情况
症状 | 治疗前(+)N | 治疗后(+)N | 改善数N | 改善率(%) |
结膜充血 | 350 | 30 | 320 | 91.43 |
眼睑红肿 | 180 | 28 | 152 | 84.54 |
眼痒溢泪 | 310 | 10 | 300 | 96.77 |
从上表可以看出,试验组疼痛、麻木、无力治疗后改善率分别为:91.43%、84.54%、96.77%。
3.2、总体疗效,见表2.
表2两组总体疗效对比表
组别 | 有效率 | 无效率 | 总有效率 |
试验组 | 98.7 | 2.3 | 99.6 |
对照组 | 78.2 | 21.8 | 82.5 |
两组总体疗效的总有效率分别为99.6%和82.5%,两组有显著性差异,p<0.01。表明试验组总体疗效明显优于对照组。
4、结论
4.1、本发明一种治疗多种眼疾的中药治疗各种眼疾的作用显著,其改善临床症状有效率为98.7%,总有效率为99.6%;
4.2、本发明使320例患者基本痊愈,其治愈率达到84.2%;
4.3、应用过程中未发现毒副作用和不良反应。
过敏试验
实验日期:2013年3月11日-4月11日
受试药物:本发明一种治疗多种眼疾的中药
试验动物:白色豚鼠,体重200-225g,共用20只。
方法:试验前把豚鼠背部的毛脱去约10cm2.试验每一天把受试药液(3×3cm2)均匀涂于背部脱毛处,10分钟后,每一小时观察皮肤反应情况一次,看皮肤有无过敏反应发生。
结果:按皮肤反应标准评分,根据反应差别判断反应程度。20支动物平均反应值为零(红斑及水肿形成总分为零),致敏率(%)(皮肤红斑及水肿动物数)亦为零。
结论:本品属无致敏性药物。
临床病例
病例一:王某,男,56岁,洛阳人,电疗师,从事保健工作。自述两年多不能在灯光下阅读。2006年3月使用本发明15分钟后能在灯光下看书读报了。20日后电话告诉我“你配的眼药真神奇,我给上百人做了试用,达到了百分之百疗效,快速3-5分钟,慢的15-30分钟即可有疗效”。
病例二:曹某,女,49岁,渭南市人,美容师。2007年7月因其母患病住院,曹某着急上火,加之陪同病人熬夜,致使双眼通红、肿痛,牙痛。使用本发明一次,眼红、肿、痛减大半,两次症状解除。后又将本发明擦到痛牙处外侧,仅用两次牙痛也好了。
病例三,崔某,男,24岁,大学生,患近视眼,左眼视力415度,右眼视力580度,且眼干、酸、涩痛,使用本发明3日,症状消失,30日后查视力:眼300度,右眼475度。3月后随访,查视力:左眼80度,右眼115度。
病例四:郭某,女,57岁,渭南市人,退休医生,骑车摔倒,左眼瘀血,肿胀,疼痛,面部紫青,已输液3日,疼痛稍减,其余症状如旧,2009年6月使用本发明20分钟后感到眼睛疼痛缓解,3日后眼部瘀血、面部紫青大半已散,肿痛消失,10日恢复正常。
病例五:苏某,男,12岁,小学生,患近视,左眼175度,右眼85度,眼胀痛,使用本发明,两次胀痛消失,45日查视力恢复正常。
病例六:赵某,女,48岁,兰州市人,某教堂长老,患糖尿病三年,2013年8月来我处求治,自述眼睛干涩、酸痛、发痒、肿胀,迎风、畏光均流泪,已服药多日,滴用多种眼药水均无效。近来发展到眼前雾障,近距离不能辩识。使用本发明10分钟后,干涩、发痒均解除,3日后,肿胀,酸痛解除,7日后雾障消失,眼睛舒适,视力提高,15日后所有症状全解除,月后随访无复发。
病例七:党某,女,78岁,大荔县人,年轻时以裁缝为职业,眼疲劳过度,再因产后上班早,致30多年前就落下眼疾,迎风流泪,畏光羞涩,酸痛,眼疲劳,2013年7月,自觉左眼昏暗,右眼严重雾障不能视物,经检查属玻璃体严重混浊,需手术治疗。后见患同病的邻居手术后双目失明、便放弃手术。2013年8月使用本发明,配合按摩上下眼眶,15日后复明。30日后所有不适症状均解除,继续使用随访无复发。
病例八:仲某,男,57岁,苏州人,针炙师。眼干涩昏花,畏光,酸困疲劳已6年,灯下不能看书报,不能正常用手机,无法写短信,为病人做治疗、看电视需戴眼镜才可以,2013年10月22日使用本发明10分钟后自觉眼睛舒适明亮,能看到书上的字,3日后不戴眼镜可以做针炙,7日后摘除眼镜,15日后可发短信了。
病例九:程某,57岁,女,北京人,中国中医科学院针炙协会工作。眼干涩、酸痛,昏花,迎风流泪5年多,灯下不能阅读,书写需戴眼镜,2013年10月26日经仲某介绍使用″视保明目液″,10分钟后眼晴舒适明亮,7日后所有不适消除,15日后摘掉眼镜,并介绍自己的朋友、学生使用本发明。
以上是近几年来用本发明治疗近千例患者的其中几个病例。使用本发明治疗多种眼疾,除眼底出血和后期青光眼外,均取得满意疗效,总之,本发明集预防,调理,治疗为一体,使用方便,价格适中,无副作用,疗效显著。
Claims (2)
1.一种治疗多种眼疾的中药,其特征在于该配方由以下重量份的原料药制成:藏红花3-5g、枸杞子9-15g、沙苑子5-15g、女贞子5-15g、车前子5-15g、五味子3-9g、青葙子5-15g、决明子1-5g、金银花9-15g、茉莉花1-5g、白菊花10-20g、石花3-9g、密蒙花1-5g、金莲花1-5g、旱莲花1-5g、谷精草6-12g、夏枯草5-15g、木贼草5-15g、夜明砂6-12g、珍珠0.5-2.5g、炉甘石3-9g、薄荷3-9g、蒲公英5-15g、千里光6-12g、黄柏3-9g、蜂胶10-20g、甘草1-5g。
2.根据权利要求1所述的一种治疗多种眼疾的中药,其特征在于各原料药的优选用量为:藏红花4g、枸杞子12g、沙苑子10g、女贞子10g、车前子10g、五味子6g、青葙子10g、决明子3g、金银花12g、茉莉花3g、白菊花15g、石花6g、密蒙花3g、金莲花3g、旱莲花3g、谷精草9g、夏枯草10g、木贼草10g、夜明砂9g、珍珠1.5g、炉甘石6g、薄荷6g、蒲公英10g、千里光9g、黄柏6g、蜂胶15g、甘草3g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410048980.2A CN103768283A (zh) | 2014-02-11 | 2014-02-11 | 一种治疗多种眼疾的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410048980.2A CN103768283A (zh) | 2014-02-11 | 2014-02-11 | 一种治疗多种眼疾的中药 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103768283A true CN103768283A (zh) | 2014-05-07 |
Family
ID=50561343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410048980.2A Pending CN103768283A (zh) | 2014-02-11 | 2014-02-11 | 一种治疗多种眼疾的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103768283A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104958513A (zh) * | 2015-07-25 | 2015-10-07 | 王璐 | 一种治疗眼赤肿痛的中药 |
CN105125767A (zh) * | 2015-09-06 | 2015-12-09 | 贾红艳 | 治疗红眼病的中药 |
CN106073363A (zh) * | 2016-07-01 | 2016-11-09 | 浙江长兴韵之农业科技发展有限公司 | 一种对近视眼有显著疗效的菊花香枕 |
CN107582771A (zh) * | 2017-07-19 | 2018-01-16 | 长春源健医疗技术有限公司 | 贴敷眼睑缓解视疲劳的贴敷制剂及其制备方法 |
CN110522815A (zh) * | 2019-09-23 | 2019-12-03 | 潘继光 | 一种治疗眼睛疾病的中药组合物及其制备方法 |
CN117257877A (zh) * | 2023-11-11 | 2023-12-22 | 山东中医药大学附属医院 | 一种治疗干眼症的中药组合物及眼用熏洗剂 |
-
2014
- 2014-02-11 CN CN201410048980.2A patent/CN103768283A/zh active Pending
Non-Patent Citations (2)
Title |
---|
张美: "除翳明目片联合更昔洛韦眼用凝胶治疗单纯疱疹性角膜炎70例", 《现代中医药》 * |
李淑琳等: "松目消疲汤联合施图伦眼液治疗视疲劳临床观察", 《新中医》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104958513A (zh) * | 2015-07-25 | 2015-10-07 | 王璐 | 一种治疗眼赤肿痛的中药 |
CN105125767A (zh) * | 2015-09-06 | 2015-12-09 | 贾红艳 | 治疗红眼病的中药 |
CN106073363A (zh) * | 2016-07-01 | 2016-11-09 | 浙江长兴韵之农业科技发展有限公司 | 一种对近视眼有显著疗效的菊花香枕 |
CN106073363B (zh) * | 2016-07-01 | 2018-02-09 | 济南市儿童医院(山东大学齐鲁儿童医院) | 一种对近视眼有显著疗效的菊花香枕 |
CN107582771A (zh) * | 2017-07-19 | 2018-01-16 | 长春源健医疗技术有限公司 | 贴敷眼睑缓解视疲劳的贴敷制剂及其制备方法 |
CN110522815A (zh) * | 2019-09-23 | 2019-12-03 | 潘继光 | 一种治疗眼睛疾病的中药组合物及其制备方法 |
CN117257877A (zh) * | 2023-11-11 | 2023-12-22 | 山东中医药大学附属医院 | 一种治疗干眼症的中药组合物及眼用熏洗剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102579918B (zh) | 治疗青光眼的中药组合物、制备方法及给药方式 | |
CN103768283A (zh) | 一种治疗多种眼疾的中药 | |
CN103961556A (zh) | 一种缓解视疲劳的铁皮石斛眼膏 | |
CN102362924B (zh) | 一种治疗眼科疾病的药物组合物及其制备方法 | |
CN102614413B (zh) | 一种治疗小儿鼻窦炎的中药组合物及其制备方法 | |
CN102861176B (zh) | 一种护眼药袋 | |
CN101601782B (zh) | 一种治疗脚癣的复方酊剂 | |
CN104971304A (zh) | 一种用于治疗干眼症的药物 | |
CN104547621A (zh) | 一种护眼中药 | |
CN105106318A (zh) | 一种治疗干眼症的中药组合物及其制备方法 | |
CN104906220B (zh) | 一种治疗带状疱疹及单纯疱疹病毒性角膜炎的中药 | |
CN104436040A (zh) | 一种治疗干眼症的药物 | |
CN104606660A (zh) | 一种治疗周围性面瘫的中药组合物 | |
CN107929670A (zh) | 一种治疗视力模糊的药物眼罩及其制备方法 | |
CN1160091C (zh) | 一种治疗结膜炎和角膜炎的药物 | |
CN102940753B (zh) | 一种治疗青光眼的药丸及制备方法 | |
CN102846113A (zh) | 一种桑叶保健枕芯及其制备方法 | |
CN113018337A (zh) | 一种治疗眼疾的复方及其制备方法与应用 | |
CN102920911B (zh) | 用于治疗角结膜干燥症的中药及其制备方法 | |
CN105194427A (zh) | 一种治疗干眼症的中药组合物及其制备方法 | |
CN101301447B (zh) | 一种治疗癫痫的中药组合物 | |
CN104771614A (zh) | 一种治疗心胆气虚型神经衰弱的药物及其制备方法 | |
CN107137603A (zh) | 一种缓解视疲劳的中药组合物、制剂及其制备方法 | |
CN102626503B (zh) | 一种舒心益智的中药口服液 | |
CN105106590A (zh) | 一种用于治疗过敏性鼻炎的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Gao Huiling Document name: the First Notification of an Office Action |
|
DD01 | Delivery of document by public notice |
Addressee: Gao Huiling Document name: Notification of an Office Action |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Gao Huiling Document name: Notification of an Office Action |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Gao Huiling Document name: Notification that Application Deemed to be Withdrawn |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140507 |
|
WD01 | Invention patent application deemed withdrawn after publication |